SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001214659-24-012340
Filing Date
2024-07-12
Accepted
2024-07-12 16:30:23
Documents
18
Period of Report
2024-07-12
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 b7112428k.htm   iXBRL 8-K 29612
2 EXHIBIT 3.1 ex3_1.htm EX-3.1 1894
3 EXHIBIT 99.1 ex99_1.htm EX-99.1 7655
7 GRAPHIC ex31-001.jpg GRAPHIC 41352
8 GRAPHIC ex31-002.jpg GRAPHIC 174681
9 GRAPHIC alzamendlogo_regmark.jpg GRAPHIC 17222
  Complete submission text file 0001214659-24-012340.txt   545262

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE alzn-20240712.xsd EX-101.SCH 2991
5 XBRL LABEL FILE alzn-20240712_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE alzn-20240712_pre.xml EX-101.PRE 22343
20 EXTRACTED XBRL INSTANCE DOCUMENT b7112428k_htm.xml XML 4031
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 241114868
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)